Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors

The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors Langenbecks Arch Surg (2011) 396:273–298 DOI 10.1007/s00423-011-0739-1 REVIEW ARTICLE The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors Simon Schimmack & Bernhard Svejda & Benjamin Lawrence & Mark Kidd & Irvin M. Modlin Received: 3 January 2011 /Accepted: 7 January 2011 /Published online: 28 January 2011 Springer-Verlag 2011 Abstract identification of the inhibitory role of the somatostatin Background Recent data demonstrate that the incidence of receptors, there is limited biological knowledge of the key gastroenteropancreatic neuroendocrine tumors (GEP-NETs) regulators of proliferation and hence a paucity of successful has increased exponentially (overall ~500%) over the last targeted therapeutic agents. IGF-I, TGFβ and a variety of three decades, thus refuting the erroneous concept of rarity. tyrosine kinases have been postulated as key regulatory GEP-NETs comprise 2% of all malignancies and in terms elements; rigorous data is still required to define predictably of prevalence, are the second commonest gastrointestinal effective and rational therapeutic strategy in an individual malignancy after colorectal cancer. Diagnosis is usually late tumor. A critical issue in the clinical management of GEP- since there is no biochemical screening test and symptoms NETs is the need to appreciate both the neuroendocrine are protean and overlooked. As a consequence, 60–80% commonalities of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Langenbeck's Archives of Surgery Springer Journals

The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors

Download PDF
26 pages

Loading next page...
 
/lp/springer-journals/the-diversity-and-commonalities-of-gastroenteropancreatic-Wz9oraIA5W

References (220)

Publisher
Springer Journals
Copyright
Copyright © 2011 by Springer-Verlag
Subject
Medicine & Public Health; Traumatic Surgery; General Surgery; Cardiac Surgery; Vascular Surgery; Abdominal Surgery; Thoracic Surgery
ISSN
1435-2443
eISSN
1435-2451
DOI
10.1007/s00423-011-0739-1
pmid
21274559
Publisher site
See Article on Publisher Site

Abstract

Langenbecks Arch Surg (2011) 396:273–298 DOI 10.1007/s00423-011-0739-1 REVIEW ARTICLE The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors Simon Schimmack & Bernhard Svejda & Benjamin Lawrence & Mark Kidd & Irvin M. Modlin Received: 3 January 2011 /Accepted: 7 January 2011 /Published online: 28 January 2011 Springer-Verlag 2011 Abstract identification of the inhibitory role of the somatostatin Background Recent data demonstrate that the incidence of receptors, there is limited biological knowledge of the key gastroenteropancreatic neuroendocrine tumors (GEP-NETs) regulators of proliferation and hence a paucity of successful has increased exponentially (overall ~500%) over the last targeted therapeutic agents. IGF-I, TGFβ and a variety of three decades, thus refuting the erroneous concept of rarity. tyrosine kinases have been postulated as key regulatory GEP-NETs comprise 2% of all malignancies and in terms elements; rigorous data is still required to define predictably of prevalence, are the second commonest gastrointestinal effective and rational therapeutic strategy in an individual malignancy after colorectal cancer. Diagnosis is usually late tumor. A critical issue in the clinical management of GEP- since there is no biochemical screening test and symptoms NETs is the need to appreciate both the neuroendocrine are protean and overlooked. As a consequence, 60–80% commonalities of

Journal

Langenbeck's Archives of Surgery – Springer Journals

Published: Jan 28, 2011

There are no references for this article.